Back to first-pass browser

First-pass extracted concept

exosomes

Candidate: concept label4 source documents7 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

extracellular vesicles

Extracted Explainers

What the tool is doing

The source summary lists exosomes as an explicitly supported delivery-related component relevant to cancer gene delivery.

Source 1DOIPubMed

Exosomes are described as extracellular vesicles involved in intercellular communication and implicated in both HIV-1 pathogenesis and therapy.

Source 2DOIPubMed

Exosomes are mentioned as an example of a novel delivery formulation being developed for CRISPR applications.

Source 3DOIPubMed

What problem it solves

In the therapeutic framing, exosomes are presented as nanocarriers for delivering payloads.

Source 2DOIPubMed

They are presented in the context of efforts to overcome in vivo packaging and delivery efficiency challenges.

Source 3DOIPubMed

Evidence Snippets

The editorial text also explicitly names supported related items such as oAd-SA, OX40L/PPT nanoparticles, oncolytic viruses, adenoviral vectors, AAVs, extracellular vesicles/exosomes, and DC-targeting lentivectors.
Evidence 1Source 1DOIPubMedprovenance
Exosomes, which are extracellular vesicles (30-150 nm) that play a key role in intercellular communication, have a dual role in HIV-1 pathogenesis and therapy.
Evidence 2Source 2DOIPubMedprovenance
development of novel delivery formulations (e.g., nanoparticles, exosomes)
Evidence 3Source 3DOIPubMedprovenance
called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies
Evidence 4Source 4DOIPubMedprovenance

Supporting Sources

Source 4primary paper2018Journal of Extracellular VesiclesDOIPubMed
1 evidence snippet1 linked claimClaim 1

Linked Claims

Claim 1delivery potentialsupports2025Source 2DOIPubMed

Exosomes are emerging as versatile therapeutic nanocarriers.

Claim 2mechanistic rolesupports2025Source 2DOIPubMed

Exosomes have a dual role in HIV-1 pathogenesis and therapy.

Claim 3mechanistic rolesupports2025Source 2DOIPubMed

HIV-1 exploits the exosome pathway by hijacking ESCRT machinery for viral budding and selectively packaging viral components such as Nef to enhance infectivity, promote immune evasion, and establish latent reservoirs.

Claim 4mechanistic rolesupports2025Source 2DOIPubMed

Host cells use exosomes to mount antiviral defense by packaging and transmitting restriction factors such as APOBEC3G to recipient cells.

Claim 5mitigation strategysupports2025Source 3DOIPubMed

Ongoing efforts to address CRISPR challenges include novel delivery formulations such as nanoparticles and exosomes, artificial intelligence-guided experimental design, and miniaturization of Cas proteins.

Quoted textsource-backed
Ongoing efforts to overcome these include the development of novel delivery formulations (e.g., nanoparticles, exosomes), artificial intelligence-guided experimental design, and miniaturization of Cas proteins.
Claim 6named examplesupports2025Source 1DOIPubMed

The editorial explicitly names oAd-SA, OX40L/PPT nanoparticles, extracellular vesicles or exosomes, and DC-targeting lentivectors as supported related items within the topic.

Claim 7evidence limitationsupports2018Source 4DOIPubMed

Claims that exosomes have exquisite and specific activities remain difficult to support experimentally because knowledge of their specific molecular machineries of biogenesis and release is still limited compared with other biophysically similar EVs.

Quoted textsource-backed
claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs